UBS lowered the firm’s price target on Treace Medical (TMCI) to $8.60 from $10 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Cautious Hold Rating for Treace Medical Concepts Amid Mixed Outlook and Revenue Uncertainty
- Treace Medical Concepts Reports Q1 2025 Financial Results
- Treace Medical reports Q1 EPS (25c), consensus (30c)
- Treace Medical sees Q2 revenue $224M-$230M, consensus $227.53M
- Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) – June 10, 2025 Deadline to Join – Contact Levi & Korsinsky LLP